by Kelley Tracy | Apr 15, 2019 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I Grant Entitled “Discovering a Small Molecule that Targets the KSHV Processivity Factor for Treating Oral and Systemic Kaposi Sarcoma” Doylestown, PA. April 15, 2019...
by Kelley Tracy | Jan 30, 2019 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Mentioned as Committed Collaborator on Business Wire Doylestown, PA. January 30, 2019 – FCCDC is pleased to announce that it has been mentioned as a committed collaborator of Cullinan Oncology in...
by Kelley Tracy | Dec 18, 2018 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Two-Year Research Contract from Intervir Doylestown, PA. December 18, 2018 – FCCDC is pleased to announce that it has been awarded a 2-year research contract from Intervir, a spin-off...
by Kelley Tracy | Sep 17, 2018 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant from the National Heart, Lung and Blood Institute of the National Institutes of Health Entitled “Soft LXR Agonists for the Treatment of Idiopathic Pulmonary...
by Kelley Tracy | Sep 5, 2018 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Research Grant from the Department of Defense Entitled “New Antifungal Agents as Topical and Systemic Therapies for Wound and Invasive Infections” Doylestown, PA. September 5, 2018...
by Kelley Tracy | Sep 3, 2018 | Uncategorized
The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II Bridge SBIR entitled “Riluzole Prodrugs for Melanoma and ALS” Doylestown, PA. September 3, 2018 – FCCDC is pleased to announce that it has been awarded a Phase II...
